Trials / Completed
CompletedNCT01133613
Double-Blind, Randomized, Single Dose Escalation Safety Study of Intraarticular Bone Morphogenic Protein (38A BMP-7) in Subjects With Osteoarthritis (OA) of the Knee
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Stryker Biotech · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to determine the safety and tolerability of two different formulations of BMP-7 for the treatment of osteoarthritis of the knee.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bone morphogenetic protein 7 | Single intraarticular injection of BMP-7 or placebo on Day 1 |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2010-05-31
- Last updated
- 2012-02-01
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01133613. Inclusion in this directory is not an endorsement.